$PBYI
PUMA BIOTECHNOLOGY, INC.

2013 Q1 Form 10-K Financial Statement

#000119312513136650 Filed on April 01, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2011 Q4 2010 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.270M $8.950M
YoY Change 77.34%
% of Gross Profit
Research & Development $9.532M $830.0K
YoY Change -9.8%
% of Gross Profit
Depreciation & Amortization $90.00K $10.00K $0.00
YoY Change 80.0%
% of Gross Profit
Operating Expenses $11.81M $9.780M $0.00
YoY Change -0.39%
Operating Profit -$11.81M
YoY Change -0.39%
Interest Expense $20.00K $0.00
YoY Change -33.33%
% of Operating Profit
Other Income/Expense, Net $26.00K -$70.00K $0.00
YoY Change 0.0%
Pretax Income -$11.78M -$9.850M $0.00
YoY Change -0.42%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.78M -$9.850M $0.00
YoY Change -0.39%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$410.7K -$522.3K $0.00
COMMON SHARES
Basic Shares Outstanding 28.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q1 2011 Q4 2010 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $118.7M $53.40M $0.00
YoY Change 136.45%
Cash & Equivalents $91.65M $53.38M $0.00
Short-Term Investments $27.10M
Other Short-Term Assets $2.100M $300.0K $0.00
YoY Change 320.0%
Inventory
Prepaid Expenses
Receivables $17.30M $0.00
Other Receivables $9.800M $0.00
Total Short-Term Assets $138.2M $53.66M $0.00
YoY Change 172.53%
LONG-TERM ASSETS
Property, Plant & Equipment $1.572M $682.0K $0.00
YoY Change 48.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.200M $1.100M $0.00
YoY Change 9.09%
Total Long-Term Assets $2.821M $1.735M $0.00
YoY Change 33.64%
TOTAL ASSETS
Total Short-Term Assets $138.2M $53.66M $0.00
Total Long-Term Assets $2.821M $1.735M $0.00
Total Assets $141.0M $55.40M $0.00
YoY Change 166.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.887M $87.00K $0.00
YoY Change 1115.32%
Accrued Expenses $14.74M $500.0K $0.00
YoY Change 65.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.63M $587.0K $0.00
YoY Change 128.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.100M $400.0K $0.00
YoY Change 57.14%
Total Long-Term Liabilities $1.100M $400.0K $0.00
YoY Change 57.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.63M $587.0K $0.00
Total Long-Term Liabilities $1.100M $400.0K $0.00
Total Liabilities $22.74M $1.026M $0.00
YoY Change 122.38%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $214.7M $64.61M
YoY Change 232.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $118.3M $54.37M $0.00
YoY Change
Total Liabilities & Shareholders Equity $141.0M $55.40M $0.00
YoY Change 166.98%

Cashflow Statement

Concept 2013 Q1 2011 Q4 2010 Q4
OPERATING ACTIVITIES
Net Income -$11.78M -$9.850M $0.00
YoY Change -0.39%
Depreciation, Depletion And Amortization $90.00K $10.00K $0.00
YoY Change 80.0%
Cash From Operating Activities -$18.48M -$1.650M $0.00
YoY Change 563.59%
INVESTING ACTIVITIES
Capital Expenditures -$180.0K -$690.0K $0.00
YoY Change -196.17%
Acquisitions
YoY Change
Other Investing Activities -$27.10M -$1.050M $0.00
YoY Change
Cash From Investing Activities -$27.28M -$1.750M $0.00
YoY Change 6333.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 56.74M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -18.48M -1.650M 0.000
Cash From Investing Activities -27.28M -1.750M 0.000
Cash From Financing Activities 0.000 56.74M 0.000
Net Change In Cash -45.76M 53.34M 0.000
YoY Change 1325.99%
FREE CASH FLOW
Cash From Operating Activities -$18.48M -$1.650M $0.00
Capital Expenditures -$180.0K -$690.0K $0.00
Free Cash Flow -$18.30M -$960.0K $0.00
YoY Change 515.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2010Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2011Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000 shares
CY2011Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
1.00 pure
CY2011Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6900000
CY2011Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.01
CY2011Q4 pbyi Number Of Investors
NumberOfInvestors
27 pure
CY2011Q4 pbyi Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P10Y
CY2011Q4 pbyi Common And Preferred Stock Shares Authorized
CommonAndPreferredStockSharesAuthorized
100000000 shares
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28676666 shares
CY2012Q2 dei Entity Public Float
EntityPublicFloat
135779108
CY2011Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2011Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q3 pbyi Merger Stock Conversion Ratio
MergerStockConversionRatio
1 pure
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
281000
CY2011Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3000
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
693000
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
64610000
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4051000
CY2011Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
270000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
54372000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2011Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1053000
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
309000
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20040000 shares
CY2011Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
149000
CY2011Q4 us-gaap Liabilities
Liabilities
1026000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
87000
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
784000
CY2011Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
10240000
CY2011Q4 us-gaap Assets
Assets
55398000
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
3082000
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55398000
CY2011Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
439000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53382000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20040000 shares
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
500000
CY2011Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
4000
CY2011Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
85000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
587000
CY2011Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7600000
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2011Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
439000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Assets Current
AssetsCurrent
53663000
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4136000
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11000
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
682000
CY2011Q4 pbyi Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
4051000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
952000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
866000
CY2012Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
19846000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1755000
CY2012Q4 us-gaap Share Price
SharePrice
16
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
213498000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33264000
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
270000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
246935 shares
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
128909000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1099000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9300000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
76000
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3704000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1212000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
787000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.75
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
121000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1067000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1013000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
18966000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28676666 shares
CY2012Q4 us-gaap Liabilities
Liabilities
22790000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.93
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
36000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
482000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22283000
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
75000
CY2012Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
138800000
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
84592000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1132000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Assets
Assets
151699000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
10638000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
151699000
CY2012Q4 us-gaap Capital Leases Lessor Balance Sheet Net Investment In Direct Financing And Sales Type Leases Current
CapitalLeasesLessorBalanceSheetNetInvestmentInDirectFinancingAndSalesTypeLeasesCurrent
10612000
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
910000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137408000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28676666 shares
CY2012Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2116250 shares
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1783000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21219000
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
276000
CY2012Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21701000
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
25800000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1906334 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1089000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Assets Current
AssetsCurrent
148972000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33266000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6960000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
276000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1479000
CY2012Q4 pbyi Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
187500000
CY2012Q4 pbyi Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
33264000
CY2012Q4 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber
1659399 shares
CY2012Q4 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
9.70
CY2012Q4 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
15262000
CY2012Q4 pbyi Common And Preferred Stock Shares Authorized Before Amendment
CommonAndPreferredStockSharesAuthorizedBeforeAmendment
110000000 shares
CY2012Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
389000
CY2012Q4 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
P9Y4M24D
CY2012Q4 pbyi Share Based Compensation Arrangement By Share Based Payment Award Option Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercised
11666 shares
CY2012 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
us-gaap Operating Income Loss
OperatingIncomeLoss
-7000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Share Based Compensation
ShareBasedCompensation
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.002
us-gaap Depreciation And Amortization
DepreciationAndAmortization
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
us-gaap Operating Expenses
OperatingExpenses
7000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
7000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
7000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4000000000 shares
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
us-gaap Net Income Loss
NetIncomeLoss
-7000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7000
us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
0.0001
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
pbyi Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
pbyi Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
CY2011Q3 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
40000
CY2011Q3 us-gaap Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
40000
CY2011Q3 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
18666733 shares
CY2011Q3 pbyi Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Shares Received
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentSharesReceived
18666733 shares
CY2012Q4 pbyi Area Of Leased Property
AreaOfLeasedProperty
13250 sqft
CY2011Q4 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2021-10-04
CY2011Q4 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1800000
CY2010 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2010 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-594000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-10157000
CY2011 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-439000
CY2011 us-gaap Other Expenses
OtherExpenses
80000
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
87000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56741000
CY2011 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7586000
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-80000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67000
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3479000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
67000
CY2011 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1053000
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.320
CY2011 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
150000
CY2011 us-gaap Depreciation And Amortization
DepreciationAndAmortization
11000
CY2011 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
150000
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1824000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1746000
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
53382000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9331000
CY2011 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
254000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
826000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56952000
CY2011 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
7586000
CY2011 us-gaap Operating Expenses
OperatingExpenses
10157000
CY2011 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
61000
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4049000
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4100000
CY2011 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
61000
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7653000
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7746529000 shares
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
670000 shares
CY2011 us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
439000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-10233000
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-76000
CY2011 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
24000
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10233000
CY2011 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
3.75
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
500000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.66
CY2011 pbyi Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
281000
CY2011 pbyi Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
150000
CY2011 pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.99
CY2012 dei Trading Symbol
TradingSymbol
PBYI
CY2012 dei Entity Registrant Name
EntityRegistrantName
PUMA BIOTECHNOLOGY, INC.
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0001401667
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Reclassifications:</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain amounts for 2011 have been reclassified to conform to the current year&#x2019;s presentation.</font></p> </div>
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4279000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-74450000
CY2012 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-464000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
395000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129214000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
18222000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1408000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-25280000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
1408000
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.48
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.75
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
159000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.420
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11666 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
11666 shares
CY2012 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Risk:</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at December&#xA0;31, 2012, were approximately $138.8 million. The Company does not believe it is exposed to any significant credit risk.</font></p> </div>
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
265000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44012000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1221000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
98000
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.75
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
84026000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24814000
CY2012 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
45000
CY2012 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
591000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49636000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129259000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
30000 shares
CY2012 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
18222000
CY2012 us-gaap Operating Expenses
OperatingExpenses
74450000
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
29213000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
29200000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19630000
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
136800
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21725986000 shares
CY2012 us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
471000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-74352000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
98000
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
346000
CY2012 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
10612000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1278000 shares
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74352000
CY2012 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
16
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates:</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates also include the cost of services provided by consultants who manage clinical trials and conduct research and clinical trials on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period. The value of stock-based compensation includes estimates based on future events which are difficult to predict. It is at least reasonably possible that a change in the estimates used to value the stock-based compensation will occur in the near term.</font></p> </div>
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50462000
CY2012 us-gaap Cost Of Reimbursable Expense
CostOfReimbursableExpense
10600000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
20719000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.38
CY2012 pbyi Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
186000
CY2012 pbyi Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
707000
CY2012 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P9Y4M24D
CY2012 pbyi Percentage Of Accounts Receivable
PercentageOfAccountsReceivable
1.00 pure
CY2012 pbyi Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2012 pbyi Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2012 pbyi Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
CY2012 pbyi Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue
CY2012 pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.90
CY2012 pbyi Operating Loss Carryforwards Expiration Dates Federal
OperatingLossCarryforwardsExpirationDatesFederal
2031
CY2012 pbyi Operating Loss Carryforwards Expiration Dates State
OperatingLossCarryforwardsExpirationDatesState
2021
us-gaap Operating Income Loss
OperatingIncomeLoss
-84614000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-903000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
482000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
185955000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-80000
us-gaap Share Based Compensation
ShareBasedCompensation
1475000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1212000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
150000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
276000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
150000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45843000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2967000
us-gaap Investment Income Interest
InvestmentIncomeInterest
102000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
137408000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34152000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
845000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
186218000
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
25808000
us-gaap Operating Expenses
OperatingExpenses
84614000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
68000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
910000
us-gaap Net Income Loss
NetIncomeLoss
-84592000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
10612000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-84592000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
21219000
pbyi Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
186000
pbyi Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
988000

Files In Submission

Name View Source Status
0001193125-13-136650-index-headers.html Edgar Link pending
0001193125-13-136650-index.html Edgar Link pending
0001193125-13-136650.txt Edgar Link pending
0001193125-13-136650-xbrl.zip Edgar Link pending
d447892d10k.htm Edgar Link pending
d447892dex1013b.htm Edgar Link pending
d447892dex211.htm Edgar Link pending
d447892dex231.htm Edgar Link pending
d447892dex311.htm Edgar Link pending
d447892dex312.htm Edgar Link pending
d447892dex321.htm Edgar Link pending
d447892dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
g447892ex10_13bpg1.jpg Edgar Link pending
g447892ex10_13bpg5.jpg Edgar Link pending
g447892g39p06.jpg Edgar Link pending
pbyi-20121231.xml Edgar Link completed
pbyi-20121231.xsd Edgar Link pending
pbyi-20121231_cal.xml Edgar Link unprocessable
pbyi-20121231_def.xml Edgar Link unprocessable
pbyi-20121231_lab.xml Edgar Link unprocessable
pbyi-20121231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending